Clinical Research Directory

Inclusion Criteria: * Histologically or cytologically documented unresectable metastatic CRC * Documented progression during or following exactly one prior regimen of systemic therapy with or without targeted therapy for metastatic CRC * Measurable disease per RECIST v1.1 * Eastern Cooperative Oncology Group performance status of 0-1 * Adequate organ and marrow function * Additional inclusion criteria may apply Exclusion Criteria: * Recent history (within last 2 years) of localized cancers that are not related to the current cancer being treated * Participants with prior CNS involvement with malignancy must have completed effective treatment of their CNS disease at least 4 weeks prior to first dose of trial intervention * Serious concurrent illness * Clinically significant proteinuria * Prior treatment with ADCs with Topo-I inhibitor payload * Prior treatment with irinotecan or Topo-I inhibitors * Receipt of systemic anti-cancer treatment, radiotherapy, or investigational agent(s) within 14days prior to trial intervention initiation * Pregnant or breastfeeding * Surgery within 4 weeks prior to first dose of trial intervention * Additional exclusion criteria may apply